Analyst Price Targets — DBVT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 18, 2025 11:46 am | Andrew Fein | H.C. Wainwright | $40.00 | $22.55 | StreetInsider | DBV Technologies S.A (DBVT) PT Raised to $40 at H.C. Wainwright |
| December 17, 2025 1:10 pm | Kristen Kluska | Cantor Fitzgerald | $48.00 | $22.92 | TheFly | DBV Technologies price target raised to $48 from $42 at Cantor Fitzgerald |
| December 17, 2025 9:32 am | Yatin Suneja | Guggenheim | $51.00 | $17.98 | StreetInsider | DBV Technologies S.A (DBVT) PT Raised to $51 at Guggenheim |
| December 15, 2025 11:39 am | Andrew Fein | H.C. Wainwright | $35.00 | $19.11 | StreetInsider | DBV Technologies S.A (DBVT) PT Raised to $35 at H.C. Wainwright |
| December 14, 2025 11:55 pm | Kristen Kluska | Cantor Fitzgerald | $42.00 | $18.38 | TheFly | DBV Technologies initiated with an Overweight at Cantor Fitzgerald |
| December 3, 2025 11:12 am | — | Guggenheim | $35.00 | $12.90 | TheFly | DBV Technologies initiated with a Buy at Guggenheim |
| May 5, 2025 10:08 am | Andrew Fein | H.C. Wainwright | $16.00 | $9.25 | TheFly | DBV Technologies price target raised to $16 from $7 at H.C. Wainwright |
Latest News for DBVT
Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new…
DBV Technologies is rated Buy following positive Phase 3 VITESSE results. My risk- and dilution-adjusted DCF yields $42 per ADS, more than double the current share price. The model assumes that 60% of diagnosed children with adequate insurance coverage ultimately initiate treatment, reflecting Viaskin's favorable safety profile, user-friendly administration, and the significant burden of avoidance-only management.…
DBV Technologies is rated a buy, with a 24% upside to a $17 FY 2027 price target as Viaskin nears BLA submission. DBVT's transition from research to commercial readiness is evident, with rising sales/marketing spend and declining research tax credits signaling operational progress. The key catalyst is the planned Q3 2026 BLA submission, expected to trigger a 10-month FDA review and potential commercial launch in…
Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that it has filed a new automatically effective shelf registration statement on Form S-3ASR (the “Registration Statement”) with the U.S.…
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DBVT.
U.S. House Trading
No House trades found for DBVT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.